Compare Intel Corp (INTC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs TransMedics Group Inc — how do they compare? Intel Corp trades at $105.31 (market cap $566.04B), while TransMedics Group Inc trades at $78.56 (market cap $2.74B). The key difference: Intel Corp is far larger — about 206.6× TransMedics Group Inc's market cap, and Intel Corp pays a 2.24% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and TransMedics Group Inc for 24 Days on average.
| INTC | TMDX | |
|---|---|---|
Market Cap | $566.04B | $2.74B |
Volume | 118,475,837 | 949,331 |
Sector | Technology | Health |
52-Week High | $140.94 | $150.42 |
52-Week Low | $33.62 | $61.99 |
Typical Hold Time | 116 Days | 24 Days |
Enterprise Value | $586.85B | $3.13B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.75, down 6.52% over the past 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages and oscillators. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.42 beating expectations of $0.21. However, Intel faces fundamental challenges with negative net income margins (-19.79%) and elevated valuation ratios (P/E of 904.17), though operating cash flow improved to $9.7 billion in 2025.
Intel's turnaround story shows early signs of progress with strong foundry revenue growth and government support, but profitability remains a concern. The stock offers potential upside to the analyst consensus price target of $111.72, though execution risks in the competitive semiconductor space and high debt levels pose significant challenges for investors seeking sustained recovery.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
